Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could many heart patients ditch Beta-Blockers? new trial investigates

NCT ID NCT05081999

Disease control Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with stable ischemic heart disease (but with normal heart pumping function and no ongoing chest pain or arrhythmias) can safely stop taking beta-blockers. About 59 participants will either continue or stop their beta-blocker and be followed for up to 4 years to compare heart events and quality of life. The goal is to see if stopping the drug reduces side effects without increasing risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta-blocker discontinuation
What this could lead to
If successful, this could show that many stable heart disease patients can safely stop taking beta-blockers, reducing side effects and medication burden.
What could go wrong
This is a small, early-phase pragmatic trial with only 59 participants, so results may not apply broadly. There is a risk that stopping beta-blockers could increase heart events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

59 people

The number who actually took part.

Started

Jan 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>21 years 2. Documented Coronary Artery Disease (CAD) defined as: * Myocardial Infarction at least 6 months prior; or * Stable ischemic heart disease (defined using one of the following tests suggestive of significant coronary artery disease): i. Positive exercise stress test ii. Positive Nuclear perfusion scan iii. Positive exercise or pharmacologic echocardiographic stress test iv. Positive magnetic resonance imaging coronary perfusion scan v. Coronary computed tomographic angiography Angiogram with stenosis ≥ 70% (or left main coronary artery ≥ 50%) or significant function disease based or positive fractional flow reserve testing by CT (FFRCT); vi. Invasive coronary angiography with ≥ 70% (or left main coronary artery ≥ 50%) or significant function disease based or positive fractional flow reserve testing (FFR) or instant wave free ratio (IFR), * Previous Percutaneous Coronary Intervention (PCI, at least 6 months prior if revascularization is performed for an MI); or * Previous Coronary Artery Bypass Grafting (CABG, at least 6 months prior if revascularization is performed for an MI) 3. Able and willing to provide informed consent Exclusion Criteria: 1. Left Ventricular Ejection Fraction \< 40% or current hospitalization for heart failure 2. Myocardial infarction \<6 months prior to randomization 3. Indication for β-blocker as determined by the treating physician (such as atrial or ventricular arrhythmias or ongoing angina not controlled by another agent) 4. Uncontrolled hypertension or uncontrolled angina symptoms (per the Investigator's discretion) 5. Non-compliance with medical therapy 6. Life expectancy \<1 year 7. Participation in another trial related to β-blockers or other anti-anginal drugs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Beta-blocker therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Beta-blocker therapy Coronary artery disease Stable ischemic heart disease

Contacts and locations

Locations

  • University of Alberta Hospital

    Edmonton, Alberta, T6G 2B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.